Echosens’ Post

At AstraZeneca our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion and how we can improve kidney health to transform health systems. https://lnkd.in/gby8rE7W

🎗 Today, on Rare Disease Day, we want to highlight the critical need for research in rare diseases. 🌟 Rare diseases affect over 300 million people globally. The limited research and medical knowledge surrounding rare diseases pose significant challenges for patients, their families, and caregivers. This scarcity of information hampers timely diagnosis, access to treatments, and adequate healthcare services. The flexibility and precision of mRNA-based therapies offer a tailored approach to treatment, potentially addressing the underlying causes of the disease rather than merely managing symptoms. At RIBOPRO, we're committed to support researchers who are at the forefront of developing innovative solutions for rare diseases. We reaffirm our commitment to those living with rare diseases and celebrate the resilience of patients, caregivers, and advocates and strive towards a future where no disease is too rare to conquer. #RareDiseaseDay #mRNA #mRNATherapy #GMP #Innovation #Awareness #GlobalHealth #StandTogether  

WHY DO I KEEP GETTING UTI'S ??? PART 1 GEN Z & Millenial population age 15-35 We are ready to talk at : "GLOVED UP & SCRUBBED IN" - follow us at #carreratelehealth , TikTok “ glovedupscrubbedin" For consultation and medical treatment asap visit Yourvipdoctor.com References: 1. Hooten TM, et al. Recurrent simple cystitis in women. https://lnkd.in/dcDgmeR6. Accessed Sept. 21, 2021. 2. Bladder infection (urinary tract infection) in adults. National Institute of Diabetes and Digestive and Kidney Diseases. https://lnkd.in/dXh7ejGM. Accessed Sept. 21, 2021. 3. Yu ASL, et al., eds. Urinary tract infection in adults. In: Brenner & Rector's The Kidney. 11th ed. Elsevier; 2020. https://lnkd.in/dvCG5Sq8. Accessed Sept. 21, 2021. 4. Cranberry. National Center for Complementary and Integrative Health. https://lnkd.in/d2TPZcrB. Accessed Sept. 21, 2021.

You already know Symphony Health’s IDV® powers commercial insights to drive brand growth. Did you know Symphony's RWD and analytics experts also provide insights for medical teams? The observational study featured below examines the underlying risk of tendon injuries among ASCVD patients.  How can we help you?

Symphony Health’s IDV® provides insights to help healthcare providers determine the underlying risk of tendon injuries and guide treatment of the patient population in this retrospective, observational study. How can we help you?

Symphony Health’s IDV® provides insights to help healthcare providers determine the underlying risk of tendon injuries and guide treatment of the patient population in this retrospective, observational study. How can we help you?

The Patient Perspective Series 🤒 At Predictive Health Intelligence, we are committed to helping clinicians detect liver disease early, before it leads to more severe conditions like cirrhosis. That’s why we developed hepatoSIGHT – a cutting-edge tool that empowers doctors to identify people at risk by analysing past medical data. During a pilot study with Somerset NHS Foundation Trust , doctors used hepatoSIGHT to flag individuals who might have undiagnosed liver disease. One of those identified was Phil, in his late 50s. Despite years of feeling unwell and frequent GP visits, his liver issues had gone undetected – until now. “I was shocked but relieved,” Phil says after receiving his diagnosis of hepatitis C, a virus that can quietly damage the liver for decades. Left untreated, hepatitis C can progress to irreversible cirrhosis, which would significantly burden both the patient and the healthcare system. Early detection allowed Phil’s doctors to intervene before the damage became severe. Phil is now receiving treatment and regular monitoring. “If you get a letter, don’t ignore it,” he advises. "It’s so much better to act early." Phil's case highlights how proactive healthcare, using tools like hepatoSIGHT, helps doctors protect patients and reduce strain on the NHS by preventing serious diseases before they escalate. #LiverHealth #PatientEngagement #PublicHealth 

Symphony Health’s IDV® is leveraged to provide insights to help healthcare providers determine the underlying risk of tendon injuries and guide treatment of the patient population in this retrospective, observational study. How can we help you? https://ow.ly/PyyZ50SJOZx

Symphony Health’s IDV® provides insights to help healthcare providers determine the underlying risk of tendon injuries and guide treatment of the patient population in this retrospective, observational study. How can we help you? https://lnkd.in/eAWQyy2K

Symphony Health’s IDV® provides insights to help healthcare providers determine the underlying risk of tendon injuries and guide treatment of the patient population in this retrospective, observational study. How can we help you?